Literature DB >> 33355024

Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives.

Kim Cao1, Louisa Abbassi1, Emanuela Romano2,3, Youlia Kirova1.   

Abstract

Introduction: The discovery of the major role of the immune system in the tumor process has led to the development of therapeutic strategies with immunotherapy. The potential systemic role of radiotherapy, (RT) used for a long time for its local action, based on its impact on immunity, is now better understood. The combination of immunotherapy and radiation therapy is currently a field of sustained research programs and has shown successful results, in non-small cell lung cancer, for example. Breast cancer (BC) was wrongly considered poorly immunogenic and put aside during accelerating progress in this new area of treatment.Areas covered: This review provides an overview of pre-clinical and clinical rationales to associate immunotherapy with radiation therapy in the management of breast cancer.Expert opinion: Immunotherapy has been used only recently in breast cancer, but clinical trials have yet to determine the place of this treatment. RT may be useful to enhance the response of breast tumors to immunotherapy. This new approach in breast cancer management is currently based on limited data but should be further investigated, especially in triple-negative breast cancer and in the neoadjuvant setting.

Entities:  

Keywords:  Immunotherapy; anticancer immunity; breast cancer; radiation therapy

Mesh:

Year:  2020        PMID: 33355024     DOI: 10.1080/14737140.2021.1868993

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  5 in total

1.  A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.

Authors:  Aki Morikawa; Milan Grkovski; Sujata Patil; Komal L Jhaveri; Kendrick Tang; John L Humm; Andrei Holodny; Kathryn Beal; Heiko Schöder; Andrew D Seidman
Journal:  Breast Cancer Res Treat       Date:  2021-06-10       Impact factor: 4.872

Review 2.  Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives.

Authors:  Fanny Ledys; Laura Kalfeist; Loick Galland; Emeric Limagne; Sylvain Ladoire
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

3.  Implantable Bioresponsive Hydrogel Prevents Local Recurrence of Breast Cancer by Enhancing Radiosensitivity.

Authors:  Zhiguang Fu; Hongqi Li; Peng Xue; Hanying Yu; Shuo Yang; Cheng Tao; Wei Li; Yingjie Wang; Jianjun Zhang; Yu Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-04-12

Review 4.  Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes.

Authors:  Dan Zheng; Xiaolin Hou; Jing Yu; Xiujing He
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

Review 5.  Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management.

Authors:  Arnaud Beddok; Paul Cottu; Alain Fourquet; Youlia Kirova
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.